Companies · Biotechnology

Noetic US Holdings LLC

Toronto · Biotechnology

Diligence memoA one-page analyst read on Noetic US Holdings LLC — recommendation, valuation, rhythm, risks.
$50.1M
Total raised · real
3
Rounds
1.5×
Latest step-up
Top 19%
Sector rank · raised
Series B
Latest stage · inferred · Fri Sep 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Noetic US Holdings LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.17× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
  • Within the normal band (117% of peer median) for its niche.
Dormant
  • Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Noetic US Holdings LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
5.2 yr record
Peak capital year was 2021 with $50.1M across 3 filings.
Market position
ahead of 82% of Biotechnology peers
Capital scale is ahead of 82% of Biotechnology peers; modeled value is above 86% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $50.1M across 3 filings.
  • Largest single filing was $30.0M on 2021-09-03.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Noetic US Holdings LLC is one of 4293 Biotechnology companies tracked from Toronto. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2021
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BPre-Seed · 2021-04-19 Raised $150K (real) Modeled valuation $5.0M (est)$150K$5.0MPre-Seed2021Series B · 2021-06-21 Raised $20M (real) Modeled valuation $523M (est)$20M$523MSeries B2021Series B · 2021-09-03 Raised $30M (real) Modeled valuation $720M (est)$30M$720MSeries B2021+$20M+$30MCumulative $50M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$150K · 2021
Series B$20.0M · 2021no Seed / Series A on file
Series B extension$30.0M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$719.7M
Base estimate est.
$60.0M
Conservative case
$2.2B
Upside case
$166.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.0M · 2021-04-192021Series B · modeled $523.4M · 2021-06-21Series B · modeled $719.7M · 2021-09-032021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
4.8 yr
Elapsed time used
4.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
2 mo
Avg between rounds
$133.7M/yr
Capital velocity
5.2 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.0× above median
This company$50.1M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.7× above median
This company$30.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$719.7M
Sector median$64.2M

Raised more than 82% of sector peers (real $). Modeled value above 86% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #42 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $999.5M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)Noetic US Holdings LLC (this company) Raised $50.1M · modeled $719.7M (est)Noetic US Holdings LLC
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.70×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$999.5M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
Noetic US Holdings LLC this companySeries B$50.1M$719.7M1.17×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$150K2021-04-19$833K$5.0M90%
Series B$20.0M2021-06-21$111.1M$523.4M90%
Series B$30.0M2021-09-03$166.7M$719.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$150K2021-04-19
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Series B$20.0M2021-06-21
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 133.3× larger than the prior — scaling up.
    • Revenue band moved $0–$1M → No revenue.
  3. Series B$30.0M2021-09-03
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
Intelligence
2021 ~Q4
Modeled next raise · ~2mo cadence
$45.0M
Modeled next size est.range $30.0M$72.0M
1.5×
Last step-up
$133.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Guy Baron1 other2021-04
Henri Koponen1 other2021-04
Meenu Chhabra Karson1 other2021-09
Vikram Chhabra Sudarsan2021-09
Registry & provenance

Noetic US Holdings LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1856095
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Noetic US Holdings Feeder LLCBiotechnologySeries B$20.6M$523.4Mnetwork2 shared operators · same sector · same stage
Molecular Assemblies, Inc.BiotechnologySeries B$50.8M$619.5Msame sector · same stage
Atia Vision, Inc.BiotechnologySeries B$51.0M$466.9Msame sector · same stage
SentreHEART IncBiotechnologySeries B$51.0M$992.2Msame sector · same stage
Aureon Biosciences, Inc.BiotechnologySeries B$51.3M$668.2Msame sector · same stage
mirOculus Inc.BiotechnologySeries B$48.4M$616.3Msame sector · same stage
Pyramid Biosciences, Inc.BiotechnologySeries B$52.0M$778.5Msame sector · same stage
Constitution Medical Investors, Inc.BiotechnologySeries B$48.4M$490.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Noetic Labs Inc.BiotechnologyPre-Seed$8.5M97%
Noetic US Holdings Feeder LLCBiotechnologySeries B$523.4M96%
Noetik Inc.BiotechnologySeries B$275.5M90%
Nok Therapeutics, Inc.BiotechnologyPre-Seed$977K87%
Noula Health Co.BiotechnologySeed$19.2M87%
Noumea Biosciences Inc.BiotechnologyPre-Seed$4.3M86%
Nobilis Therapeutics IncBiotechnologyPre-Seed$27.6M86%
Nomax Therapeutics, IncBiotechnologySeed$25.1M86%
Frequently asked
How much funding has Noetic US Holdings LLC raised?
Noetic US Holdings LLC has raised approximately $50.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Noetic US Holdings LLC's estimated valuation?
Provath's modeled valuation for Noetic US Holdings LLC is approximately $719.7M (modeled range $60.0M–$2.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Noetic US Holdings LLC at?
Noetic US Holdings LLC's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Sep 03.
What does Noetic US Holdings LLC do and where is it based?
Noetic US Holdings LLC operates in the Biotechnology sector, based in Toronto.
Explore related

See where Noetic US Holdings LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Noetic US Holdings LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.